CD4 and neoplasm: Importantly, BDCA‐1+ cDC2 levels may predict responses to PD‐1 blockade therapy, even in tumors with low BDCA‐3+ cDC1 content, particularly when tumor cells express MHCII and engage CD4+ T cells [38].